Brief: Praxis Precision Medicines Terminates 2024 Sales Agreement With Jefferies - SEC Filing
05/09/2025 22:51
Sept 5 (Reuters) - Praxis Precision Medicines Inc PRAX.O: PRAXIS PRECISION MEDICINES INC - TERMINATES 2024 SALES AGREEMENT WITH JEFFERIES - SEC FILING PRAXIS PRECISION MEDICINES INC - ENTERS 2025 SALES AGREEMENT WITH TD SECURITIES - SEC FILING Source text: [ID:n0001104659-25-087865] Further company coverage: PRAX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Praxis Precision Medicines
See all newsUS RESEARCH ROUNDUP-Arxis, Cigna, Vylor
Brief: Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Praxis Precision Medicines, Inc. reports results for the quarter ended June 30 - Earnings Summary
Praxis Precision Q2 net loss widens on higher expenses
Brief: Praxis Precision Q2 EPS USD -2.87